RT Journal Article
T1 Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
A1 Romero, Alejandro
A1 Ramos, Eva
A1 Lopez-Muñoz, Francisco
A1 Gil-Martin, Emilio
A1 Escames, Germaine
A1 Reiter, Russel J
K1 COVID-19
K1 Central nervous system
K1 Melatonin
K1 Neuroinvasion
K1 Neuroprotection
K1 SARS-CoV-2
AB The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.
PB Springer New York LLC
YR 2020
FD 2020-08-05
LK http://hdl.handle.net/10668/16074
UL http://hdl.handle.net/10668/16074
LA en
NO Romero A, Ramos E, López-Muñoz F, Gil-Martín E, Escames G, Reiter RJ. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? Cell Mol Neurobiol. 2022 Apr;42(3):489-500.
DS RISalud
RD Apr 8, 2025